Genmab to Hold 2024 RD Update and ASH Data Review Meeting
| GMAB Stock | USD 22.96 0.28 1.23% |
About 52% of Genmab AS's investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Genmab AS suggests that some traders are interested. The current market sentiment, together with Genmab AS's historical and current headlines, can help investors time the market. In addition, many technical investors use Genmab AS stock news signals to limit their universe of possible portfolio assets.
Genmab |
Media Release Event to be held virtually via live webcast and archived on www.genmab.com Copenhagen, Denmark December 11, 2024 Genmab AS will hold its 2024 RD Update and ASH Data Review Meeting today, December 11, 2024 at 1100 AM Eastern Time . The event will take place virtually in English and can be attended via live webcast. To register for the webcast, click httpsgenmab-post-ash-2024.open-exchange.net. An archive of the webcast will be avai
Read at finance.yahoo.com
 |
Genmab AS Fundamental Analysis
We analyze Genmab AS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Genmab AS using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Genmab AS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Asset
Total Asset Comparative Analysis
Genmab AS is currently under evaluation in total asset category among its peers. Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Genmab AS Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Genmab AS stock to make a market-neutral strategy. Peer analysis of Genmab AS could also be used in its relative valuation, which is a method of valuing Genmab AS by comparing valuation metrics with similar companies.
Peers
Genmab AS Related Equities
| PCVX | Vaxcyte | 1.26 |
| ||
| TERN | Terns Pharmaceuticals | 1.86 |
| ||
| EWTX | Edgewise Therapeutics | 2.45 |
| ||
| ASND | Ascendis Pharma | 2.97 |
| ||
| DAWN | Day One | 4.03 |
| ||
| APLS | Apellis Pharmaceuticals | 4.33 |
| ||
| LEGN | Legend Biotech | 5.80 |
| ||
| CYTK | Cytokinetics | 6.76 |
| ||
| BPMC | Blueprint Medicines | 7.06 |
| ||
| AKRO | Akero Therapeutics | 7.29 |
| ||
| TVTX | Travere Therapeutics | 7.48 |
| ||
| AMLX | Amylyx Pharmaceuticals | 8.54 |
| ||
| ALEC | Alector | 14.02 |
|
Complementary Tools for Genmab Stock analysis
When running Genmab AS's price analysis, check to measure Genmab AS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genmab AS is operating at the current time. Most of Genmab AS's value examination focuses on studying past and present price action to predict the probability of Genmab AS's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genmab AS's price. Additionally, you may evaluate how the addition of Genmab AS to your portfolios can decrease your overall portfolio volatility.
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |